http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10201523-B2

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e72dc577da85163736854f83176517d0
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-704
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K36-37
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-517
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-337
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-365
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-517
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K36-37
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-704
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-365
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-337
filingDate 2014-09-12-04:00^^<http://www.w3.org/2001/XMLSchema#date>
grantDate 2019-02-12-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_780e4baefba163de2653e0f87cfbcc7b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fbe2446b6474f37fe6cd587c0bef7386
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_23fc84e78a1857e23f1d174ef97e61c2
publicationDate 2019-02-12-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber US-10201523-B2
titleOfInvention Use of wilforlide A for overcoming chemotherapy resistance
abstract The invention provides compositions comprising wilforlide A for overcoming drug resistance in cancer therapy, particularly in the treatment of cancers which have exhibited resistance to treatment by chemotherapeutic drugs. Methods and compositions for treating a cancer are disclosed. The method administers to a patient in need thereof a combination of wilforlide A and a chemotherapeutic drug. Wilforlide A and chemotherapeutic drug are administered in a combined amount effective to treat the cancer. The cancer being treated is at least in part resistant to treatment by the chemotherapeutic drug alone.
priorityDate 2013-09-13-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2012122825-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-102443039-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2015038896-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2005330253-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2014031543-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8357690-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2012308567-A1
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID379
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID19649
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226505476
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226395937
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226395938
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID21122770
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID208908
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226395939
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID65191
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID745
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID123631
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID176870
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6711468
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6433344
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID45051774
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226399616
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID11177
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226399177
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226395471
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID64780
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID3213
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226396020
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226408482
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226395926
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226395927
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226394438
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226399366
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID24749
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226395318
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID347468
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID30323
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID124886
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID148124
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226393829
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226493290
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226395500
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID46214236
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226393830
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226493291
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID11645942
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID11046239
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226400160
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226396417
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226400161
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226396418
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID31703
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID13075888
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226396419

Total number of triples: 84.